Paul Richardson, MD

Over the past two decades, the U.S. Food and Drug Administration (FDA) has approved a number of new treatments for patients with myeloma – most recently the anti-CD38 monoclonal antibodies – and new ways to measure disease response. This innovation has given clinicians the opportunity to redefine the goals of disease treatment and the value [...]